Glomerular Pla2r Immune Complex Deposition C5937410
A kidney disease where immune proteins targeting PLA2R deposit in kidney filters, often causing protein loss in urine. Treatment may include immunosuppressants.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Changes in urination or swelling
(renal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Proteinuria
(renal)Edema
(renal)Hypertension
(renal)Hematuria
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Immunosuppressive therapy
Immunosuppressive agents are used to reduce anti-PLA2R antibody production and decrease immune complex deposition in the glomerular basement membrane, helping to preserve kidney function.
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
ACE inhibitors or ARBs
These medications help reduce proteinuria and slow disease progression by decreasing intraglomerular pressure and providing renoprotective effects.
Additional treatment options
Regular proteinuria monitoring
Frequent assessment of proteinuria levels and kidney function through urine tests and blood work helps track disease progression and treatment response.
monitoringSodium-restricted diet
Reducing sodium intake helps manage fluid retention and blood pressure, supporting overall kidney function and reducing edema associated with proteinuria.
dietaryBlood pressure control
Maintaining optimal blood pressure through lifestyle modifications and medication adherence helps protect kidney function and reduces cardiovascular risk.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Glomerular Pla2r Immune Complex Deposition C5937410?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021.
Couser WG, Beck LH. Membranous Nephropathy and Anti-PLA2R Antibodies. N Engl J Med. 2022.
Hoxha E, Reinhard L, Stahl RAK. Rituximab for PLA2R-Positive Membranous Nephropathy. J Am Soc Nephrol. 2023.
Liu Y, Wang X, Zhang J, Chen L. Efficacy of Immunosuppressive Therapy for Anti-PLA2R Positive Membranous Nephropathy: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2020.
Medication Comparisons
Compare medications used to treat Glomerular Pla2r Immune Complex Deposition C5937410. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy